从微小残留病角度看恶性血液病的个体化治疗

Minimal residual disease-directed individualized therapy for hematological malignancies

微小残留病(MRD)已被用于包括急性白血病在内的恶性血液病的复发预警、指导治疗方法选择等方面。文章基于第64届美国血液学会(ASH)年会报道的MRD相关内容,以急性髓系白血病为主要着眼点讨论MRD指导的恶性血液病的个体化治疗进展。

Minimal residual disease(MRD)has been used for warning of relapse and guiding the therapy selection for hematological malignancies including acute leukemia.Based on MRD-related content reported at the 64th American Society of Hematology(ASH)Annual Meeting,this article discusses the progress of MRD-directed individualized therapy for hematological malignancies with a primary focus on acute myeloid leukemia.